ArticleCancer medicine2025
Utility of a Novel High-Sensitivity Multiplex Companion Diagnostic Test Using Formalin-Fixed Paraffin-Embedded Cell Block Materials of Non-small Cell Lung Cancer.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
- Erratum issued
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFormalin-fixed paraffin-embedded (FFPE) tissue is the standard material for companion diagnostic tests (CDx). Although cytological specimens can be useful, their low tumor content (TC) poses challenges. Recently, a high-sensitivity CDx, the "Lung Cancer Compact Panel (cPANEL)," with a recommended TC of 5%, was introduced into clinical practice. This CDx achieves high detection sensitivity by selecting specific genes for analysis, processing them separately, and performing sequence at sufficient depth. This approach enables the detection of mutations even when they are present in only small amounts within the sample. This study aimed to evaluate the utility of cPANEL using FFPE cell block (CB) with a low TC.
methodsWe analyzed FFPE-CB pleural fluid samples from 26 patients diagnosed with malignant pleural effusion originating from lung adenocarcinoma. TC was quantified using AI-equipped image analysis software, and samples with a TC of less than 10%-the minimum threshold for single-CDx-were selected for CDx analysis. To confirm that cPANEL has better sensitivity than single-CDx, which has high detection power, and that it is advantageous in low TC samples such as FFPE-CB, we compared the two CDx assays based on the EGFR-positive rate using samples that did not meet the TC criterion for single-CDx.
resultsMost FFPE-CB had low TC levels, with only approximately 27% meeting the TC criteria for the widely used multi-CDx. Furthermore, over 60% of the samples fell below the 10% threshold for a single-CDx. Despite the low TC, EGFR mutations were partially detected, with cPANEL achieving a higher detection rate than that of single-CDx (68.8% vs. 50.0%).
conclusionsAlthough cPANEL is classified as a multi-CDx, it demonstrated superior sensitivity compared with that of single-CDx. It proved effective even for FFPE-CB samples with very low TC, making it a promising tool to enhance the use of cytological samples for CDx in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.